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This study aimed to assess the long-term course of pulmonary arterial hypertension related to infection with
human immunodeficiency virus (PAHRH) and the influence of antiretroviral therapy (ART) on its character-
istics. We retrospectively analyzed all 47 patients in the Swiss HIV Cohort Study in whom PAHRH was
diagnosed. Among 35 patients who underwent follow-up Doppler echocardiography, the right ventricular
systolic pressure over right atrial pressure gradient increased by a median of 25 mm Hg in 9 patients who
had not received ART, decreased by a median of 3 mm Hg in 12 patients who had received nucleoside analogs,
and decreased by a median of 21 mm Hg in 14 patients who had received highly active ART (HAART) (P !
). Among all 47 patients, median duration of survival after PAHRH diagnosis was 2.7 years. HAART.005
significantly decreased mortality due to PAHRH as well as other causes. This study suggests a beneficial effect
of combination ART in patients with PAHRH.
The association between pulmonary arterial hyperten-
sion (PAH) and HIV infection is well established [1–
7]. It was first described in 1987 in an HIV-infected
patient with hemophilia and membranoproliferative
glomerulonephritis [8]. To date, ∼220 cases of PAH
related to infection with HIV (PAHRH) have been re-
ported. The incidence of PAHRH is estimated to be
∼0.5% [2, 3], which is ∼2500 times greater than that
of primary pulmonary hypertension (PPH) in the gen-
eral population [9]. The pathogenesis of PAHRH re-
mains unclear. There is no evidence that HIV infects
pulmonary artery endothelial cells. Neither HIV nor its
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proteins has been identified in the pulmonary vascular
endothelium of patients with PAHRH [10]. It has been
suggested that the increased incidence of PAH in pa-
tients with HIV might be the result of an indirect role
of the virus, stimulating the host to release proinflam-
matory cytokines or growth factors that would result
in PAH [11–14]. Only a small percentage of HIV-in-
fected patients, however, develop PAH. This supports
the existence of an individual susceptibility to the de-
velopment of this disease. A recent study suggests that
this susceptibility could have a genetic basis and might
be determined by major histocompatibility complex al-
leles, particularly HLA-DR6 and HLA-DR52 [15], but
preliminary unpublished examinations suggest that
these alleles are not present in HIV-infected patients
with PAH. On the other hand, the histopathology of
HIV-associated pulmonary vasculopathy is similar to
that of PPH [1, 2, 6, 10, 16, 17], suggesting similar
etiological mechanisms. This is supported by data
showing that PAHRH also responds to treatment with
the endothelin-receptor antagonist bosentan, which is
effective in patients with PPH [18, 19].
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The records of the Swiss HIV Cohort Study (SHCS) [20]
contain one of the largest cohorts with PAHRH. In this study,
we retrospectively evaluated all patients with PAHRH in the
SHCS. One goal was to describe the long-term clinical and
echocardiographic course of the disease.
The best therapeutic approach for patients with PAHRH is
unknown [21, 22]. Few reports describe the efficacy of treat-
ment for PAHRH. Drugs used in the treatment of PAHRH
include anticoagulation therapy [22, 23], diuretics [22], vaso-
dilators (calcium channel blockers [24, 25], intravenous epo-
prostenol [1, 26, 27], inhaled iloprost [28], sildenafil [29, 30],
and bosentan [18]), and antiretroviral treatment (ART) [24,
27, 31–33]. In a previous study, Opravil et al. [24] suggested
that ART decreases the right ventricular systolic pressure
(RVSP) over right atrial pressure (RAP) gradient in patients
receiving ART, compared with an increased gradient in patients
who were not receiving ART. On the basis of improvements in
the pressure gradient over time in patients who received ART,
it was recommended that all patients be treated with PAHRH,
irrespective of their CD4 lymphocyte counts. On the other
hand, an accelerated course of the disease has been reported
in 2 patients who received HAART [31]. Thus, another goal
of the present study was to evaluate a larger number of patients
over a longer follow-up period to determine whether the pres-
sure gradient could be influenced by ART and whether mor-
tality attributable to PAHRH could be decreased.
PATIENTS AND METHODS
Patients. We retrospectively evaluated all 47 patients who
received a diagnosis of PAHRH between 1988 and December
2001 and who were observed within the SHCS. Some patients
were examined prospectively with successive echocardiography.
Twenty-nine of the cases we describe have not been reported
previously. Diagnostic criteria for PAHRH were as follows: el-
evation of RVSP over RAP of 130 mm Hg, assessed by con-
tinuous-wave Doppler echocardiography; exclusion of pul-
monary emboli by lung perfusion scan or autopsy; normal left
ventricular function and no evidence of congenital or valvular
heart disease (evaluated by 2-dimensional echocardiography);
exclusion of obstructive or restrictive pulmonary disease on the
basis of clinical examination and pulmonary function tests; and
no history of previous ingestion of anorectics or use of intra-
venous amphetamine therapy. The diagnosis of PAH was in-
vasively confirmed in 8 patients who underwent right heart
catheterization. The catheterization values were in good con-
cordance with echocardiographic findings. To assess the pos-
sible effect of ART on the course of PAHRH, patients were
divided into 3 groups on the basis of the treatment received
between the time of PAHRH diagnosis and the performance
of the final echocardiography (or the final clinical follow-up,
for those who did not undergo successive echocardiography):
those who received !4 weeks of ART or no ART at all, those
who were treated with 1 or 2 nucleoside analog reverse-
transcriptase inhibitors (NRTIs) only, and those who received
HAART, which was defined as triple therapy including at least
1 protease inhibitor or non-NRTI.
Statistical analysis. Comparisons between the 3 treatment
groups were evaluated using x2 analysis or Kruskal-Wallis test-
ing with Dunn’s multiple comparison posttest, as appropriate.
Predictors for decreases in the pressure gradient were assessed
by multiple logistic regression analysis. The risk of death and
predictors for survival were calculated by means of Kaplan-
Meier life-table methods and multivariable Cox regression
analysis. Analyses were conducted using GraphPad Prism, ver-
sion 4.00 for Windows (GraphPad Software), and Stata soft-
ware, version 8.2 (Stata).
RESULTS
Demographic and clinical data. Between January 1988 and
December 2001, 47 patients fulfilled our diagnostic criteria for
PAHRH (table 1). There were 25 men (53%) and 22 women
(47%), with a mean age at the time of diagnosis of 34.4 years
(range, 24–67 years). Forty-six patients were white and 1 was
black. Injection drug use (IDU) was the most common risk
factor for HIV infection and was reported by 33 patients (70%).
Other risk factors reported included male-male sex by 7 patients
(15%), both heterosexual sex and IDU by 3 patients (6%), and
heterosexual sex by 4 patients (9%). The median time interval
between the diagnosis of HIV infection and the diagnosis of
PAHRH was 7.7 years. At the time of diagnosis of PAHRH, 17
patients were in US Centers for Disease Control and Prevention
HIV disease stage A, 18 were in stage B, and 12 were in stage
C. The median CD4 lymphocyte count at the time of diagnosis
was 169 cells/mL (range, 1–870 cells/mL). Twenty-eight patients
had CD4 cell counts of !200 cells/mL, 14 patients had CD4 cell
counts of 200–499 cells/mL, and 5 patients had CD4 cell counts
of 1500 cells/mL. The median New York Heart Association
(NYHA) functional class value was 2.
The most common presenting symptom leading to the di-
agnosis of PAHRH was shortness of breath in 83% of the pa-
tients. Other presenting symptoms included peripheral edema
in 26% of the patients, syncope in 6%, and chest pain in 6%.
An electrocardiogram, which was available for 42 patients,
showed signs of PAH in 79%. Findings on chest radiographs
were consistent with PAH for 74% of the patients. The mean
elevation (SD) of RVSP over RAP was mm Hg,63 16
ranging from 38 to 115 mm Hg at the time of diagnosis. No
patient had stenosis of the pulmonary artery, and no patient
had systemic hypertension. The 3 treatment groups did not
differ with regard to their baseline characteristics, except that
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Table 1. Patient demographic and clinical characteristics at the time of diagnosis of pulmonary arterial
hypertension associated with HIV infection.
Characteristic
Treatment group
Overall
population
(n p 47)
No ART
during follow-up
(n p 13)
Only NRTIs
during follow-up
(n p 15)
HAART
during follow-up
(n p 19)
Male sexa 25/47 (53) 6/13 (46) 7/15 (47) 12/19 (63)
Age, years 33 (29–36) 34 (28–36) 31 (28–33) 36 (32–41)
Median date of PAHRH diagnosis January 1994 May 1993 March 1993 February 1998
HIV transmission category
IDU 33 (70) 13 (100) 10 (67) 10 (53)
MSM 7 (15) 0 (0) 2 (13) 5 (26)
Heterosexual sex 4 (9) 0 (0) 3 (20) 1 (5)
IDU and heterosexual sex 3 (6) 0 (0) 0 (0) 3 (16)
CDC HIV disease stage
A 17 8 3 6
B 18 4 4 10
C 12 1 8 3
CD4 cell count, cells/mL 169 (82–371) 270 (105–515) 83 (22–179) 141 (82–295)
DRVSP-RAP, mm Hg 60 (50–75) 64 (52–78) 64 (52–75) 59 (49–75)
NYHA class 2.0 (2.0–2.0) 2.0 (1.5–2.0) 2.0 (2.0–2.0) 2.0 (2.0–2.0)
NOTE. Data are no. (%) of patients or median values (interquartile range), unless otherwise indicated. The 3 subgroups
did not differ significantly in baseline characteristics (x2 or Kruskal-Wallis test, as appropriate), except for a later date of diagnosis
in the HAART group. ART, antiretroviral therapy; CDC, US Centers for Disease Control and Prevention; IDU, injection drug use;
MSM, men who have sex with men; NRTI, nucleoside analog reverse-transcriptase inhibitor; NYHA, New York Heart Association;
DRVSP-RAP, elevation of right ventricular systolic pressure over right atrial pressure, measured by echocardiography.
a Data are no. of males/total no. of patients in the study (%).
the baseline date for patients receiving HAART was substantially
later, and patients who did not receive any ART were all IDUs.
Incidence over time. The incidence of PAHRH was cal-
culated as the percentage of the total number of SHCS partic-
ipants in whom PAHRH was diagnosed during each year. The
highest incidence numbers were observed between 1990 and
1995, with a maximum of 0.24% in 1993. From 1996, con-
currently with the introduction of HAART, the incidence fell
significantly to 0.06%–0.09% (table 2).
Treatment. The median follow-up duration was 2.7 years
(range, 3 days to 10.5 years). The drugs used in the treatment
of PAHRH included diuretics in 17 patients, calcium-channel
blockers in 6 patients, oral anticoagulation agents in 13 patients,
intravenous epoprostenol in 1 patient, and inhaled iloprost in
7 patients (a possible effect of iloprost therapy on the final
echocardiography was present only for 4 patients; in the re-
maining patients, iloprost therapy was initiated only after the
final echocardiography was performed). After the diagnosis of
PAHRH, ART was prescribed to 34 patients. Among them, 15
patients were treated with NRTIs only, whereas 19 patients
received HAART.
Hemodynamic data and effect of ART. One or several
follow-up Doppler echocardiograms were available for 35 pa-
tients to document the continued course of PAHRH (table 3).
When stratified by the anti-HIV treatment received between
the first and final echocardiography, the 3 treatment groups
had similar baseline RVSP-RAP gradients. The median change
in the pressure gradient between the first and final echocar-
diography was +25 mm Hg in the 9 patients who did not receive
ART, 3 mm Hg in the 12 patients who received NRTIs, and
21 mm Hg in the 14 patients who received HAART (P !
, by the Kruskal-Wallis test, with significant differences be-.005
tween the non-ART and NRTIs groups and the non-ART and
HAART groups, by Dunn’s multiple comparison test). The 3
groups also differed significantly in the proportion of patients
in whom the pressure gradient increased or decreased by 110
mm Hg during the follow-up period. Because no relevant
changes occurred in systemic blood pressure or heart rate, de-
creases in forward cardiac output could be excluded as a cause
for the observed changes in the RVSP-RAP pressure gradient.
The time course of the pressure gradient during the observation
period is plotted in figure 1. Although the NYHA functional
class values increased during the follow-up period for patients
who were not receiving ART and for patients who were re-
ceiving NRTIs, patients receiving HAART showed stable to
slightly decreasing values, illustrating clinical stabilization or
improvement. In a multiple logistic regression analysis that was
adjusted for age, sex, IDU, and AIDS stage at the time of
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Table 2. Incidence of newly diagnosed cases of pulmonary
hypertension (PH) per year as percentage of the total number of
Swiss HIV Cohort Study (SHCS) participants with a follow-up visit
during that year.
Year
New PH
cases, no.
Active SHCS
participants, no.
Yearly incidence
of new PH
diagnoses, %
1988 1 1433 0.07
1989 1 2109 0.05
1990 6 2832 0.21
1991 2 3246 0.06
1992 4 3263 0.12
1993 7 2953 0.24
1994 4 2751 0.15
1995 5 2910 0.17
1996 3 3344 0.09
1997 3 3929 0.08
1998 4 4440 0.09
1999 3 4839 0.06
2000 3 5203 0.06
2001 1 5432 0.02
NOTE. The trend showing decreasing incidence since 1995 was statis-
tically significant ( , by Poisson regression analysis).Pp .027
PAHRH diagnosis, both overall duration of ART (OR, 1.79 per
year of treatment; 95% CI, 1.11–2.90 per year of treatment;
) and overall duration of HAART (OR, 1.94 per yearPp .017
of treatment, 95% CI, 1.17–3.25 per year of treatment; Pp
) were significant predictors of a pressure gradient decrease.011
of 110 mm Hg.
Mortality. Thirty-one of 47 patients died during the fol-
low-up period; 16 were still living at the end of the study.
Median survival duration after the diagnosis of PAHRH was
2.7 years (range, 2 days to 10.5 years). Of the reported fatal
cases, 10 deaths (32%) were attributable to the consequences
of PAH (including right heart failure, cardiogenic shock, and
sudden death), 16 deaths (52%) were attributable to HIV in-
fection or other diagnoses, and 5 patients died of an unknown
cause (16%). All 13 patients who were not treated with ART
and all 15 patients who were treated with NRTIs only died,
with an estimated median survival duration of 1.5 and 1.7 years,
respectively (Kaplan-Meier estimates) (figure 2). In contrast,
only 3 of 19 patients treated with HAART died. PAHRH was
the direct cause of death in 5 (38%) of 13 of untreated patients,
in 4 (27%) of 15 of those treated with nucleoside analogs, and
in 1 (5%) of 19 of those treated with HAART ( ). InPp .065
a multivariable Cox regression analysis that was adjusted for
age, sex, IDU, and AIDS stage at the time of PAHRH diagnosis,
HAART significantly decreased the risk of death (hazard ratio
[HR], 0.075; 95% CI, 0.02–0.28; ).P ! .001
The mortality rate was 67% (24 of 36 patients) among in-
dividuals whose risk for HIV infection was IDU, which was
comparable with the 64% mortality rate (7 of 11 patients) in
the other risk groups. However, all untreated patients who died
belonged to the IDU group, illustrating that ART is more dif-
ficult to initiate in this risk group.
The mortality rate among the 35 patients who underwent
follow-up echocardiography was significantly lower in those
who received HAART (table 3). In a multivariable Cox re-
gression analysis that was adjusted for age, sex, IDU, and AIDS
stage at the time of PAHRH diagnosis, both HAART (HR, 0.034;
95% CI, 0.005–0.23; ) and a pressure gradient decreaseP ! .001
of 110 mm Hg (HR, 0.97; 95% CI, 0.94–0.998; ) sig-P ! .05
nificantly reduced the risk of dying.
DISCUSSION
Over a 13-year period, PAHRH was diagnosed in 47 patients.
This represents a prevalence of 0.4% within the entire HIV-
infected population in the SHCS (which involved 11,894 par-
ticipants through the end of 2001) and an incidence of 0.02%–
0.24% per year. The prevalence we observed is only slightly less
than that observed in previous studies, in which the prevalence
was estimated to be 0.5% [2, 3]. Although the number of newly
diagnosed cases per year is relatively small, the decreasing in-
cidence of PAHRH from 1996 through 2001 correlates well
with the introduction of HAART and, in addition, indirectly
supports the efficacy of HAART for treatment or prevention
of PAH. This is in contrast to the retrospective study by Pugliese
et al. [34], which found that PAH cases were more frequent
among patients currently receiving HAART (2.0%) than among
patients who received previous treatment with ART regimens
(0.7%). However, Pugliese et al. [34] do not mention the num-
ber of untreated HIV-infected patients in their center, and the
increased number of patients with PAHRH during receipt of
HAART may simply reflect the recommendation known at that
time that all patients with PAHRH should be treated with
HAART.
In accordance with previous publications, the demographic
data of out patients confirm that PAHRH occurs in all stages
of HIV infection without an obvious relation to immune de-
ficiency. Nineteen of our patients (40%) had CD4 lymphocyte
counts of 1200 cells/mL, which corresponds to the ratio in other
reports [1, 24]. IDU and male-male sex predominated among
our patients, but PAHRH occurs in all risk groups. Among our
patients, there was a small predominance of men over women.
In 35 patients (74%), a minimum of 1 follow-up Doppler
echocardiogram was available, allowing us to determine the
course of the pressure gradient over time. Doppler echocar-
diography is recognized as a useful and reliable tool for doc-
umenting the time course of PAH [35]. Because shifts in the
pressure gradient occurred without concurrent changes in sys-
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Table 3. Time course in 35 patients with echocardiographic follow-up data.
Characteristic
Treatment group
No ART
during follow-up
(n p 9)
Only NRTIs
during follow-up
(n p 12)
HAART
during follow-up
(n p 14)
Follow-up duration, years 2.4 (0.8–5.3) 1.7 (1.1–3.1) 4.8 (2.5–8.5)
Duration of ART after PH diagnosis, years … 0.9 (0.3–1.5) 3.6 (1.9–6.9)
Duration of HAART after PH diagnosis, years … … 3.4 (1.9–5.6)
CD4 cell count at baseline, cells/mLa 300 (115–515) 82 (26–155) 240 (95–396)c
Final known CD4 cell count, cells/mLb 120 (68–385) 39 (9–189) 373 (163–510)d
Final known HIV-1 RNA load !400 copies/mL 1/4 (25) 0/3 (0) 9/12 (75)
CDC HIV disease stage
Stage B/C 2 (22) 1 (8) 1 (7)
Stage C 2 (22) 1 (8) 1 (7)
Cause of death
Cardiac reasons 5 (56) 4 (33) 0 (0)
HIV-related or other diagnoses 3 (33) 5 (42) 2 (14)f
Unknown 1 (11) 3 (25) 0 (0)
Total 9 (100) 12 (100) 2 (14)
Time from first to last echocardiography, years 1.4 (0.4–4.1) 1.0 (0.3–1.8) 3.6 (1.9–8.1)
No. of echocardiograms per patient 3.0 (2.0–5.0) 2.5 (2.0–4.0) 3.0 (2.0–6.5)
DRVSP-RAP, mm Hg
First 60 (47–84) 62 (54–76) 60 (51–83)
Final 93 (64–98) 58 (49–66) 50 (36–61)
Change +25 (+6 to +35) 3 (24 to +4) 21 (30 to 6)d
Increase by 110 mm Hg 6 (67) 2 (17) 2 (14)e
Decrease by 110 mm Hg 0 (0) 5 (42) 10 (71)f
NYHA class
Time of diagnosis 2.0 (1.0–2.5) 2.0 (2.0–2.0) 2.0 (2.0–2.0)
Change +1.0 (+1.0 to + 2.0) +1.0 (0.5 to +2.0) 0 (1.0 to 0)c
Treatment
Diuretics 4 (44) 5 (42) 6 (43)
Digoxin 1 (11) 3 (25) 2 (14)
Calcium-channel blockers 2 (22) 2 (17) 1 (7)
Vasodilators other than calcium channel
blockers (iv epoprostenol, inhaled iloprost) 0 (0) 1 (8) 3 (21)
NOTE. Data are no. (%) of patients or median values (interquartile range). ART, antiretroviral therapy; CDC, US Centers for Disease
Control and Prevention; IDU, injection drug use; NRTI, nucleoside analog reverse-transcriptase inhibitor; NYHA, New York HeartAssociation;
PH, pulmonary hypertension; DRVSP-RAP, elevation of right systolic ventricular pressure over right atrial pressure.
a n p 9, 12, and 13 for each column, respectively.
b n p 8, 10, and 14 for each column, respectively.
c , by the Kruskal-Wallis test for comparisons between the 3 groups.P ! .05
d , by the Kruskal-Wallis test for comparisons between the 3 groups.P ! .005
e , by the x2 test for comparisons between the 3 groups.P ! .02
f , by the x2 test for comparisons between the 3 groups.P ! .005
temic blood pressure or heart rate, a decrease in forward cardiac
output could be excluded as a cause for the observed changes
in the RVSP-RAP pressure gradient.
In our patient population, HAART and, to a lesser degree,
treatment with NRTIs resulted in a significant beneficial effect
on the course of the pressure gradient, and HAART led to a
decreased or stabilized NYHA functional class value. In the
group of 35 patients for whom follow-up Doppler echocar-
diograms were available, the RVSP-RAP gradient increased by
a median of 25 mm Hg in 9 patients who were not treated
with ART, decreased by a median of 3 mm Hg in 12 patients
who were treated with NRTIs, and decreased by a median of
21 mm Hg in 14 patients who received HAART ( ).P ! .005
It must be emphasized, however, that the treatment groups—
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Figure 1. Time course of the elevation of right ventricular systolic pressure over right atrial pressure (DRVSP-RAP), assessed by continuous-wave
Doppler echocardiography, in patients receiving no antiretroviral therapy (ART) (left), compared with patients receiving nucleoside analog reverse-
transcriptase inhibitors (NRTIs) only (middle) and patients receiving HAART (right). The x axis of the middle graph is expanded because of the shorter
follow-up period for these patients.
Figure 2. Probability of survival from the time of diagnosis of pul-
monary hypertension until the end of the follow-up period, stratified by
the type of antiretroviral therapy received ( , by the log-rank test).P ! .0001
ART, antiretroviral therapy; NRTI, nucleoside analog reverse-transcriptase
inhibitor.
in particular, the HAART group—are not fully comparable and
represent periods with different standards of care and means
of clinical assessment. In many patients treated with HAART,
the virus load was undetectable, but HIV RNA PCR was not
available before the era of HAART. The possible correlation
between suppressed virus load and echocardiogram findings
could not be evaluated, because these assessments were fre-
quently performed at different time points. Other baseline pa-
rameters may have had prognostic influence. The multiple
logistic regression analysis and multivariable Cox regression
analysis have therefore been adjusted for age, sex, IDU, and
AIDS at baseline. None of these parameters showed any sig-
nificant predictive effect on the hemodynamic response or sur-
vival, either in the univariable or in the multivariable analysis.
Seven patients treated with ART also received intermittent
therapy with inhaled iloprost. During the 2 months of intra-
venous treatment, 1 of these 7 patients also received epopros-
tenol. In 3 of these 7 patients, all Doppler echocardiographic
studies were performed without iloprost or epoprostenol treat-
ment, and thus the results were not influenced by these agents.
In 4 patients, ART was administered concomitant with inhaled
iloprost therapy. In these 4 patients, the pressure gradient de-
creased, which was likely influenced by the concomitant treat-
ment with inhaled iloprost. When these 4 patients were re-
moved from the analysis, the median change in the pressure
gradient was +1 mm Hg in 11 patients treated with NRTIs (not
including data for 1 patient) and 19 mm Hg in patients
receiving HAART (not including data for 3 patients), indicating
that concomitant treatment with iloprost and epoprostenol did
not change the overall results in any major way. None of the
patients were treated with bosentan.
The median survival duration was similar between untreated
patients and those who received NRTIs but was significantly
improved among those who received HAART. This is not sur-
prising, according to the known benefit of combination ART
[36, 37]. Because HAART decreased mortality directly attrib-
utable to PAH as well as mortality due to HIV infection and
other causes, the reduction in the right ventricular workload
seems to have directly translated into a clinical benefit.
Even if HIV or its proteins have not been identified in the
pulmonary vascular smooth muscle or endothelium in patients
with PAHRH [10], HIV infection induces a chronic inflam-
matory state and persisting immune activation [38]. Instead,
it is hypothesized that HIV-infected macrophages may release
abnormal types and/or quantities of cytokines that sequentially
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lead to enhanced leukocyte adherence, growth factor secretion,
and endothelial proliferation [4]. In fact, in several studies, high
levels of endothelin-1, IL-1a, IL-6, and platelet-derived growth
factor in patients with PAHRH have been found [11, 12, 39].
HAART downregulates viral replication and leads to a decrease
in abnormal rates and/or types of T cell activation [40]. It is
conceivable that reduction of the chronic stimulation of the
immune system brought about by ART might also decrease the
(still unknown) driving force behind the development of PPH.
Recently, human herpesvirus 8 (HHV-8) has been suggested as
a possible etiologic agent in PPH [41], but no data exist on
the association between HHV-8 and PAHRH. Because HAART
itself decreases the incidence of Kaposi sarcoma (which is as-
sociated with HHV-8) and decreases circulating HHV-8 viremia
[20, 42], further study regarding the possible association be-
tween HHV-8 and PAHRH seems to be warranted.
In conclusion, an indirect pathogenic relationship between
HIV infection and the incidence of PAH is strongly suggested
in the face of the improved hemodynamic parameters in our
patients who received ART, particularly HAART. This study
confirms the recommendation in a previous study [24] to treat
all patients with PAHRH with HAART, irrespective of their CD4
lymphocyte counts.
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